Advent Capital Management’s AbbVie ABBV Stock Holding History

Advent Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-50	Closed	-$2K	–	519
2015 Q1	$2K	Buy	+50	New	+$3.02K	﹤0.01%	461

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Advent Capital Management's ABBV Position: Q2 2026 in Review

Advent Capital Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 15,000 shares — an estimated $3.26M sold.

Advent Capital Management first reported a position in ABBV in Q1 2015 and held it in 23 quarters. The position peaked at $6M in Q1 2022. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Advent Capital Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Advent Capital Management sold 15,000 AbbVie shares in Q2 2026, an estimated $3.26M.
Advent Capital Management first reported a position in AbbVie in Q1 2015 and held it in 23 quarters.
Advent Capital Management's AbbVie position peaked at $6M in Q1 2022.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Advent Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.